Résultats de recherche

Retour
1 - 10 de 555 Résultats de recherche
 -  08 Octobre 2020

 -  08 Octobre 2020

 Ipsen to present 12 abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress taking place jointly with the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)

Attachment...

 -  04 Mai 2020

 -  04 Mai 2020

Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program

Attachment...

 -  25 Mars 2020

 -  25 Mars 2020

Ipsen provides COVID-19 update

Attachment...

 -  24 Janvier 2020

 -  24 Janvier 2020

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria

Attachment...

 -  23 Mai 2020

 -  23 Mai 2020

New surveys show over 80% of patients with spasticity and cervical dystonia treated with botulinum toxin-A experience debilitating symptom recurrence

...

 -  26 Mars 2020

 -  26 Mars 2020

Ipsen provides update on palovarotene clinical programs

...

 -  19 Mai 2020

 -  19 Mai 2020

Ipsen announces publication of first matching-adjusted indirect comparison of Cabometyx® (cabozantinib) versus regorafenib in advanced hepatocellular carcinoma in Advances in Therapy

Attachment...

 -  19 Mai 2020

 -  19 Mai 2020

Ipsen annonce la publication dans Advances in Therapy de la première comparaison indirecte ajustée par appariement entre Cabometyx® (cabozantinib) et le régorafénib dans le traitement du carcinome hépatocellulaire avancé

Pièce jointe...

 -  11 Mars 2020

 -  11 Mars 2020

Ipsen data presented during ENETS Annual Conference 2020 capture new patient and healthcare professional insights in the treatment of NETs and acromegaly

Attachment...

 -  05 Novembre 2019

 -  05 Novembre 2019

Proposed reclassification of Ipsen shares held by Mayroy

Mayroy files a request with the AMF for a waiver to the obligationto file a public offer...

1 … 52 53 54 55 56